Progress of Risperdal Lawsuits to be Addressed During Meeting in Philadelphia Court of Common Pleas

Share Article

Bernstein Liebhard LLP is representing Risperdal lawsuit plaintiffs in cases involving the medication’s alleged association with gynecomastia, and expects next month’s meeting to address issues relevant to those claims.

Free Case Review
Our Firm is currently representing numerous Risperdal lawsuit plaintiffs who allegedly developed gynecomastia due to treatment with the antipsychotic medication.

Hundreds of Risperdal lawsuits (http://www.risperdallawsuit2014.com/) that have been consolidated in a mass tort program underway in Pennsylvania’s Philadelphia Court of Common Pleas continue to move forward. According to court documents, the Court has scheduled a meeting for May 12th at 9:30 a.m., at which time the status of product liability claims involving Risperdal’s alleged association with gynecomastia (male breast growth) and other complications will be addressed. (In Re: Risperdal Litigation, Case Number 100300296)

“Our Firm is currently representing numerous Risperdal lawsuit plaintiffs who allegedly developed gynecomastia due to treatment with the antipsychotic medication. We are looking forward to next month’s meeting, as it will likely address matters relevant to our client’s claims, including discovery and issues pertaining to the litigation’s ongoing bellwether trial program,” said Sandy A. Liebhard, a partner at Bernstein Liebhard LLP, a nationwide law firm representing the victims of defective drugs and medical devices. The Firm continues to provide Risperdal lawsuit consultations to men and boys who allegedly experienced excessive breast growth due to their use of the medication.

Risperdal Litigation
Court documents indicate that more than 1,320 Risperdal lawsuits have been filed in the Pennsylvania mass tort program, all of which accuse Johnson & Johnson’s Janssen Pharmaceuticals unit of concealing data linking the drug to gynecomastia and other serious complications. In addition, the complaints allege that Janssen failed to provide adequate warnings regarding these risks, and improperly promoted Risperdal for unapproved, off-label uses, including certain pediatric uses that weren’t cleared by the U.S. Food & Drug Administration until 2006.

Court records indicate that the litigation embarked on a bellwether trial program this year involving cases that allege a connection between Risperdal and gynecomastia. The first trial ended on February 24th, with the jury awarding $2.5 million to an autistic man who experienced excessive breast growth after taking Risperdal as a child. (Case No. A-196444) The second trial concluded on March 20th, with the jury finding that Johnson & Johnson and Janssen’s warnings about male breast growth were inadequate. However, the plaintiff was not awarded any monetary damages because the panel concluded that he had not proven that Risperdal caused his condition. (Case No. 130301803)

“This mass tort program was established to allow Risperdal lawsuits that put forth similar allegations of fact to undergo coordinated proceedings. The Court’s bellwether trial program is expected to continue, and these cases may provide more insight into how juries could decide similar claims involving gynecomastia,” says Sandy A. Liebhard.

Risperdal patients who allegedly developed gynecomastia connected with its use may be eligible to file their own lawsuit. To learn more about the ongoing Risperdal litigation, please contact Bernstein Liebhard LLP for a free case review by visiting the Firm’s website, or by calling 800-511-5092.

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The National Law Journal has recognized Bernstein Liebhard for twelve consecutive years as one of the top plaintiffs' firms in the country. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
800-511-5092

ATTORNEY ADVERTISING. © 2015 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Sandy A. Liebhard, Esq.
info (at) consumerinjurylawyers (dot) com
http://www.risperdallawsuit2014.com/
https://plus.google.com/115936073311125306742?rel=author

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Sandy A. Liebhard
Follow us on
Visit website